EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.62 (-3.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close20.44
Bid19.75 x 1800
Ask20.21 x 3000
Day's Range19.78 - 20.57
52 Week Range15.02 - 25.31
Avg. Volume3,135,930
Market Cap6.022B
Beta (5Y Monthly)1.72
PE Ratio (TTM)10.13
EPS (TTM)1.96
Earnings DateFeb 25, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.42
  • GILD or EXEL: Which Is the Better Value Stock Right Now?

    GILD or EXEL: Which Is the Better Value Stock Right Now?

    GILD vs. EXEL: Which Stock Is the Better Value Option?

  • Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?
    Simply Wall St.

    Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...

  • Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

    Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

    Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Business Wire

    Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

    Exelixis, Inc. (Nasdaq: EXEL) today announced its key priorities and anticipated milestones for 2020-21, including generating top-line data from key clinical trials, completing enrollment of ongoing studies, initiating new pivotal trials, and progressing its mid-stage and early pipeline. The company intends to make appropriate investments to maximize the clinical development opportunities for CABOMETYX® (cabozantinib), which Exelixis believes could lead to as many as four additional approved indications by year-end 2021, while concurrently working to advance a pipeline of potential new Exelixis medicines through internal drug discovery and business development.

  • 2019 Review: Top Hedge Fund Stocks vs. Exelixis, Inc. (EXEL)
    Insider Monkey

    2019 Review: Top Hedge Fund Stocks vs. Exelixis, Inc. (EXEL)

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]

  • Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

    Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

    A low-key week for the biotech sector, with a few pipeline and regulatory updates.

  • Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

    Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

    Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.

  • Business Wire

    Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

    Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference being held next week in San Francisco. Exelixis’ presentation has been scheduled for Tuesday, January 14, 2020 at 7:30 PM EST / 4:30 PM PST.

  • Business Wire

    Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

    Exelixis, Inc. (NASDAQ: EXEL) today announced that based on continued encouraging efficacy and safety data, the company plans to further expand the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The cohort, which was previously expanded from 30 to 80 patients in July 2019, will now include up to 130 patients.

  • Business Wire

    Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

    Exelixis, Inc. (NASDAQ:EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX®), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ®), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and renal cell carcinoma (RCC).

  • Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

    Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

    Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.

  • Benzinga

    The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...

  • Business Wire

    Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis, Inc. (Nasdaq: EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF V600 mutation-positive advanced melanoma. Genentech, Inc. (a member of the Roche Group), Exelixis’ collaborator and the sponsor of the IMspire150 trial, informed the company that the study met its primary endpoint of progression-free survival (PFS). Adding atezolizumab to cobimetinib and vemurafenib helped to reduce the risk of disease worsening or death, compared to placebo plus cobimetinib and vemurafenib.

  • Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL)
    Insider Monkey

    Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay?
    Simply Wall St.

    How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay?

    Michael Morrissey became the CEO of Exelixis, Inc. (NASDAQ:EXEL) in 2010. This analysis aims first to contrast CEO...

  • Business Wire

    Exelixis Announces Webcasts of Investor Conference Presentations in December

    – Presentations to be webcast on www.exelixis.com –

  • Why Did Farallon Capital Get Out of These 3 Biotech Stocks?

    Why Did Farallon Capital Get Out of These 3 Biotech Stocks?

    Since 1986, Farallon Capital has built a proven record for success, mainly from steady hands at the helm and consistent returns for investors. The firm was founded by Tom Steyer, with $15 million in initial capital, and when he retired as managing director in 2012 Farallon had grown to hold over $20 billion in assets under management.Steyer’s successor, Andrew Spokes, has continued the firm’s strategy of ‘absolute return’ investing, assuming every investment has a guaranteed return. As far as stocks are concerned, this investment strategy tends toward the conservative – but it also tends to ensure a good return.So, it makes sense that Farallon would get rid of underperforming or overly risky stocks. In the last quarter, the firm backed out of three high-profile biotech firms.Let’s dive into the TipRanks database to learn more about the doubts and why Farallon is backing out of these biotechs.Sarepta Therapeutics (SRPT)This Massachusetts-based firm takes a focus on genetic disorders, especially muscular dystrophy. Sarepta has one approved product, Exondys 51, a treatment for Duchenne muscular dystrophy, and approved for patients with a confirmed mutation in the DMD gene. With another 16 projects in the pipeline, Sarepta is well positioned for the future. The company is a collaborator on an additional 9 projects.Biotech is a sector with inherent high overhead, high risk, and long lead times to profitability, so Sarepta, like many biotechs focused on clinical phase research, operates at loss. In Q3, the company’s EPS loss increased by 103% year-over-year, to $1.14, even though revenues, at $99 million, showed a 26% yoy gain. The quarterly report noted increased expenditures as the root cause of the increased earnings loss.Interestingly, Farallon divested 500,000 shares – the firm’s entire position in Sarepta. It was a major move by a major fund, that signals a serious lack of confidence in SRPT going forward.At least one Wall Street analyst would agree with Farallon’s position. Hartaj Singh, writing from Oppenheimer, set a Hold on the stock. He wrote, “We believe that with management's focus on early stage gene therapy trials, investor sentiment is slowly shifting to a more skeptical stance on other projects." The analyst added, "While management's (and the Street's) focus has been on the development pipeline, namely SRP-9001, we have highlighted the role a golodirsen CRL could have on the P&L in the medium term. Updates on regulatory actions remain a potential catalyst for 2019, but we keep vigilant on the progress of commercial supply development for SRP-9001. Feasibility of these outlined timelines could be put to the test in 2020." (To watch Singh's track record, click here)Other analysts might have to seriously disagree with Singh. The Street considers Sarepta stock a Strong Buy. According to TipRanks analytics, out of 13 analysts, 12 are bullish, while only one is sidelined. The consensus price target stands at $184.91, showing a 73% upside from the current share price. (See Sarepta stock analysis on TipRanks)Exelixis (EXEL)Located in Alameda, not far from Silicon Valley, Exelixis develops medications for the treatment of a variety of cancers. Unlike many small- to mid-cap biotech companies, Exelixis operates at a profit, thanks to three approved medications on the market. Two of the drugs, Cabometyx and Cometriq, are brand names for cabozantinib, used to treat thyroid and renal cancers, while the third, Cotellic, is used for treatment of melanoma.Having several products on the market for common cancers puts EXEL stock in the black. The company has been running a profit and beating earnings expectations since early in 2018. In its most recent quarterly report, EXEL posted an EPS of 31 cents, beating the 20-cent forecast by an impressive 55%. Still, the EPS was down 24% from the year-ago quarter. The drop in year-over-year earnings came even as revenues, at $271.7 million, increased 20% in the same period.The slide in earnings, despite strong revenues, indicate slower sales than expected – and that induced Farallon to shed 42% of its Exelixis holdings. In all, Farallon sold off 1.25 million shares of EXEL in Q3. Farallon still owns more than $28 million worth of EXEL. It will be interesting to see what the fund does with this stock going forward.5-star BMO analyst George Farmer looks at EXEL and says Hold. He notes the company’s profits, but is cautious on sales. He noted, “Weak Cabometyx sales of $187M, well below ours/consensus of $203M/ $198M, were recorded in spite of a 4.5% price increase last July. We believe this result, ostensibly due to a backlog of patients slow to progress, creates a new overhang on shares…” (To watch Farmer's track record, click here)However, it looks like other analysts aren’t ready to tap out just yet. This stock’s Moderate Buy consensus rating is based on 6 Buys and 3 Holds given in the past three months. Shares are priced at $16.80 and have an average price target of $24.78, indicating upside potential of 48%. (See Exelixis stock analysis on TipRanks)Amarin (AMRN)The company’s omega-3 based drug, Vascepa, is available by prescription as a treatment for hypertriglyceridemia, an indicator for heart disease, and has been shown to have a clear beneficial effect in preventing heart attack. Vascepa was approved and put on the market in 2013, and forecasts show it reaching well over $2 billion in sales by 2024. However, the omega-3 niche is starting to fill up, and Vascepa is facing increasing competition.That competition has not impacted Amarin’s profits – yet. The company’s Q3 results showed $112 million in revenues, a 103% year-over-year gain, and the company has $677 million in cash-on-hand. Vascepa prescription were up 9.9% from Q2, to 865,000 orders.Amarin saw its shares surge as high as 50% this month. The boost came on the heels of FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vascepa, to include patients at risk of a heart attack and other major adverse cardiovascular events. The FDA is set to make a final decision on December 28, 2019.Spokes, however, saw risk here, and Farallon’s sale of Amarin shares was its largest biotech divestment. The firm sold off 2,249,400 shares in AMRN in Q3, reducing its holding by 53% to just over 2 million shares.Two Wall Street analysts become more skeptical about Amarin's valuation earlier this month. Joel Beatty of Citigroup, wrote, “We believe Vascepa is an effective drug and anticipate sales accelerating significantly over the next year, however, we believe this is now already priced into the stock.” Beatty downgraded AMRN from Buy to Hold, although his $27 target suggests an upside of 29% for AMRN. (To watch Beatty's track record, click here)Oppenheimer analyst Leland Gershell is even more downbeat on Amarin. He said, in his recent initiation of coverage report, “We believe that a ~12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models.” Gershell’s price target, $7, implies a strong 66% downside here. (To watch Gershell's track record, click here)Overall, Amarin still gets a Moderate Buy from the analyst consensus, with 7 Buys, 2 Holds, and 1 Sell set in recent weeks. The stock has a $27.50 average stock-price forecast, indicating a 35% upside from the $20.42 trading price. (See Amarin stock analysis on TipRanks)

  • Business Wire

    Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

    – Presentation to be webcast on www.exelixis.com –

  • Business Wire

    Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

    – Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –

  • Business Wire

    Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

    -- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (EXEL) announced today that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive results from a phase 3 pivotal trial of esaxerenone, a product of the companies’ prior research collaboration, in patients with diabetic nephropathy. Esaxerenone is a novel mineralocorticoid receptor (MR) blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo.

  • Thomson Reuters StreetEvents

    Edited Transcript of EXEL earnings conference call or presentation 30-Oct-19 9:00pm GMT

    Q3 2019 Exelixis Inc Earnings Call

  • Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

    Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

    Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

  • Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

    Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

    Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Tod

  • Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 31% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 31% Undervaluation?

    In this article we are going to estimate the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the foreast...